Provided by Tiger Trade Technology Pte. Ltd.

INDIVIOR PLC

36.76
-1.0700-2.83%
Post-market: 36.44-0.3200-0.87%19:04 EDT
Volume:1.82M
Turnover:67.13M
Market Cap:4.48B
PE:37.46
High:37.90
Open:37.51
Low:36.62
Close:37.83
52wk High:41.00
52wk Low:11.04
Shares:121.92M
Float Shares:104.00M
Volume Ratio:0.89
T/O Rate:1.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.9812
EPS(LYR):0.0152
ROE:12.20%
ROA:22.65%
PB:-31.12
PE(LYR):2,426.24

Loading ...

Indivior Eliminates Chief Scientific Officer Role, Realigns Leadership

TIPRANKS
·
Yesterday

Indivior eliminates chief scientific officer role; Heidbreder departs end-2026

Reuters
·
Yesterday

Indivior Pharmaceuticals Inc - to Eliminate Chief Scientific Officer Position Effective June 1, 2026 - SEC Filing

THOMSON REUTERS
·
Yesterday

Indivior Pharmaceuticals, Inc : Stifel Raises Target Price to $52 From $42

THOMSON REUTERS
·
May 06

A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Q1 Beat, Raised 2026 Guidance And Buyback News

Simply Wall St.
·
May 05

Sector Update: Health Care

MT Newswires Live
·
May 04

Indivior Pharmaceuticals Enters $175 Million Accelerated Share Repurchase Agreement

MT Newswires Live
·
May 04

Indivior announces $175M accelerated share repurchase program

TIPRANKS
·
May 04

Indivior Announces $175 Million Accelerated Share Repurchase

THOMSON REUTERS
·
May 04

Indivior Earnings Call Highlights SUBLOCADE-Fueled Momentum

TIPRANKS
·
May 02

Indivior Pharmaceuticals, Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
Apr 30

Indivior Pharmaceuticals Q1 revenue rises 19%, beats estimates

Reuters
·
Apr 30

Indivior Pharmaceuticals Q1 Revenue USD 317 Million Vs. IBES Estimate USD 272.8 Million

Reuters
·
Apr 30

Indivior Q1 GAAP net income rises 89% to $89 million; revenue climbs 19% to $317 million

Reuters
·
Apr 30

Indivior Q1 Adj. EPS $0.96 Beats $0.66 Estimate, Sales $317.000M Beat $272.840M Estimate

Benzinga
·
Apr 30

Indivior Pharmaceuticals, Inc - Revises FY 2026 Net Revenue Guidance to $1,215 Mln-$1,285 Mln

THOMSON REUTERS
·
Apr 30

Indivior Pharmaceuticals, Inc - Revises FY 2026 Adj Ebitda Guidance to $620 Mln-$660 Mln

THOMSON REUTERS
·
Apr 30

Indivior Pharmaceuticals, Inc - Revises FY 2026 Sublocade Net Revenue Guidance to $950 Mln-$990 Mln

THOMSON REUTERS
·
Apr 30

Addex Therapeutics publishes 2025 annual report

Reuters
·
Apr 30

Addex FY25 net loss widens to CHF 6.7 million; cash falls to CHF 1.6 million

Reuters
·
Apr 30